Immunotherapeutic activity of a recombinant combined gB-gD-gE vaccine against recurrent HSV-2 infections in a guinea pig model

Roberto Manservigi, Anna Boero, Rafaela Argnani, Elisabetta Caselli, Silvia Zucchini, Vivì Miriagou, Penelope Mavromara, Michele Cilli, Maria Pia Grossi, Pier Giorgio Balboni, Enzo Cassai

Research output: Contribution to journalArticle

Abstract

The guinea pig model of recurrent genital herpes simplex virus type 2 (HSV-2) infection was used to test the immunotherapeutic activity of a glycoprotein subunit vaccine. Vaccine formulation consisted of three recombinant herpes simplex virus (HSV) glycoproteins, namely gB1s, gD2t and gE1t, plus aluminium hydroxide [Al(OH) 3)] adjuvant. One month after viral challenge, infected animals were therapeutically immunised by seven subcutaneous injections of a low dose of antigens with a weekly interval for the first five and a fortnightly interval for the last two administrations. Results showed that the treatment was highly effective in ameliorating the recidivist pathology of animals, suggesting that this kind of vaccine formulation and administration may be helpful for therapeutic intervention in humans affected by recurrent herpes infections.

Original languageEnglish
Pages (from-to)865-872
Number of pages8
JournalVaccine
Volume23
Issue number7
DOIs
Publication statusPublished - Jan 4 2005

Fingerprint

Human herpesvirus 2
Human Herpesvirus 2
Virus Diseases
guinea pigs
glycoproteins
Glycoproteins
Guinea Pigs
Vaccines
animal pathology
vaccines
Aluminum Hydroxide
Herpes Genitalis
herpes simplex
aluminum hydroxide
Subunit Vaccines
subunit vaccines
subcutaneous injection
Simplexvirus
Subcutaneous Injections
infection

Keywords

  • Herpes simplex virus vaccine
  • Immunotherapy
  • Viral glycoproteins

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this

Manservigi, R., Boero, A., Argnani, R., Caselli, E., Zucchini, S., Miriagou, V., ... Cassai, E. (2005). Immunotherapeutic activity of a recombinant combined gB-gD-gE vaccine against recurrent HSV-2 infections in a guinea pig model. Vaccine, 23(7), 865-872. https://doi.org/10.1016/j.vaccine.2004.08.025

Immunotherapeutic activity of a recombinant combined gB-gD-gE vaccine against recurrent HSV-2 infections in a guinea pig model. / Manservigi, Roberto; Boero, Anna; Argnani, Rafaela; Caselli, Elisabetta; Zucchini, Silvia; Miriagou, Vivì; Mavromara, Penelope; Cilli, Michele; Grossi, Maria Pia; Balboni, Pier Giorgio; Cassai, Enzo.

In: Vaccine, Vol. 23, No. 7, 04.01.2005, p. 865-872.

Research output: Contribution to journalArticle

Manservigi, R, Boero, A, Argnani, R, Caselli, E, Zucchini, S, Miriagou, V, Mavromara, P, Cilli, M, Grossi, MP, Balboni, PG & Cassai, E 2005, 'Immunotherapeutic activity of a recombinant combined gB-gD-gE vaccine against recurrent HSV-2 infections in a guinea pig model', Vaccine, vol. 23, no. 7, pp. 865-872. https://doi.org/10.1016/j.vaccine.2004.08.025
Manservigi, Roberto ; Boero, Anna ; Argnani, Rafaela ; Caselli, Elisabetta ; Zucchini, Silvia ; Miriagou, Vivì ; Mavromara, Penelope ; Cilli, Michele ; Grossi, Maria Pia ; Balboni, Pier Giorgio ; Cassai, Enzo. / Immunotherapeutic activity of a recombinant combined gB-gD-gE vaccine against recurrent HSV-2 infections in a guinea pig model. In: Vaccine. 2005 ; Vol. 23, No. 7. pp. 865-872.
@article{d31633574c874bbdbe0c6250b1aeb432,
title = "Immunotherapeutic activity of a recombinant combined gB-gD-gE vaccine against recurrent HSV-2 infections in a guinea pig model",
abstract = "The guinea pig model of recurrent genital herpes simplex virus type 2 (HSV-2) infection was used to test the immunotherapeutic activity of a glycoprotein subunit vaccine. Vaccine formulation consisted of three recombinant herpes simplex virus (HSV) glycoproteins, namely gB1s, gD2t and gE1t, plus aluminium hydroxide [Al(OH) 3)] adjuvant. One month after viral challenge, infected animals were therapeutically immunised by seven subcutaneous injections of a low dose of antigens with a weekly interval for the first five and a fortnightly interval for the last two administrations. Results showed that the treatment was highly effective in ameliorating the recidivist pathology of animals, suggesting that this kind of vaccine formulation and administration may be helpful for therapeutic intervention in humans affected by recurrent herpes infections.",
keywords = "Herpes simplex virus vaccine, Immunotherapy, Viral glycoproteins",
author = "Roberto Manservigi and Anna Boero and Rafaela Argnani and Elisabetta Caselli and Silvia Zucchini and Viv{\`i} Miriagou and Penelope Mavromara and Michele Cilli and Grossi, {Maria Pia} and Balboni, {Pier Giorgio} and Enzo Cassai",
year = "2005",
month = "1",
day = "4",
doi = "10.1016/j.vaccine.2004.08.025",
language = "English",
volume = "23",
pages = "865--872",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "7",

}

TY - JOUR

T1 - Immunotherapeutic activity of a recombinant combined gB-gD-gE vaccine against recurrent HSV-2 infections in a guinea pig model

AU - Manservigi, Roberto

AU - Boero, Anna

AU - Argnani, Rafaela

AU - Caselli, Elisabetta

AU - Zucchini, Silvia

AU - Miriagou, Vivì

AU - Mavromara, Penelope

AU - Cilli, Michele

AU - Grossi, Maria Pia

AU - Balboni, Pier Giorgio

AU - Cassai, Enzo

PY - 2005/1/4

Y1 - 2005/1/4

N2 - The guinea pig model of recurrent genital herpes simplex virus type 2 (HSV-2) infection was used to test the immunotherapeutic activity of a glycoprotein subunit vaccine. Vaccine formulation consisted of three recombinant herpes simplex virus (HSV) glycoproteins, namely gB1s, gD2t and gE1t, plus aluminium hydroxide [Al(OH) 3)] adjuvant. One month after viral challenge, infected animals were therapeutically immunised by seven subcutaneous injections of a low dose of antigens with a weekly interval for the first five and a fortnightly interval for the last two administrations. Results showed that the treatment was highly effective in ameliorating the recidivist pathology of animals, suggesting that this kind of vaccine formulation and administration may be helpful for therapeutic intervention in humans affected by recurrent herpes infections.

AB - The guinea pig model of recurrent genital herpes simplex virus type 2 (HSV-2) infection was used to test the immunotherapeutic activity of a glycoprotein subunit vaccine. Vaccine formulation consisted of three recombinant herpes simplex virus (HSV) glycoproteins, namely gB1s, gD2t and gE1t, plus aluminium hydroxide [Al(OH) 3)] adjuvant. One month after viral challenge, infected animals were therapeutically immunised by seven subcutaneous injections of a low dose of antigens with a weekly interval for the first five and a fortnightly interval for the last two administrations. Results showed that the treatment was highly effective in ameliorating the recidivist pathology of animals, suggesting that this kind of vaccine formulation and administration may be helpful for therapeutic intervention in humans affected by recurrent herpes infections.

KW - Herpes simplex virus vaccine

KW - Immunotherapy

KW - Viral glycoproteins

UR - http://www.scopus.com/inward/record.url?scp=10444282017&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10444282017&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2004.08.025

DO - 10.1016/j.vaccine.2004.08.025

M3 - Article

C2 - 15603886

AN - SCOPUS:10444282017

VL - 23

SP - 865

EP - 872

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 7

ER -